QuantLogix ← CRL scorecard
📅 CRL Earnings Preview
Charles River Laboratories International, Inc.
Next report (est.)
11/26/2026
Countdown
80 days
EPS growth YoY
-102.8%
Revenue growth YoY
-2.7%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/05/2026 ±3.4% +11.4% under-priced
05/07/2026 ±4.4% -0.0% over-priced
11/05/2025 ±3.9% -5.7% under-priced
08/06/2025 ±3.4% -10.3% under-priced
05/07/2025 ±4.3% +18.7% under-priced
11/06/2024 ±3.3% +13.5% under-priced
08/07/2024 ±5.3% -12.6% under-priced
05/09/2024 ±2.3% -2.2% over-priced
Across these reports, options implied an average ±3.8% move vs an actual average of 9.3% — the stock stayed inside the implied band 25% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $-0.03 $1.0B $-760,000
Q1 FY2026 $-0.30 $996M $-15M
Q4 FY2025 $-5.56 $994M $-276M
Q3 FY2025 $1.10 $1.0B $56M
Analyst posture
Buy / Strong Buy
17
Hold
6
Sell
0
Stable: +3 net change 30d
Live 5-factor engine read: Strong Buy · 64/100 Full scorecard →
Get alerted before every CRL report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on CRL before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Charles River Laboratories International, Inc. (CRL) reports in 80 days, with the next report estimated for 11/26/2026. Across the last 8 reports, options priced an average ±3.8% earnings move while the stock actually moved 9.3% on average — the market has tended to under-price CRL's earnings risk. Fundamentals into the print: EPS down 102.8% year-over-year, revenue down 2.7%. QuantLogix's live 5-factor engine currently reads CRL as a strong buy at 64/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →